Clinical Trial Update: A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX) [Phase 4]

View source ↗

Summary

Phase 4 AVATAX trial evaluating first-line bevacizumab with paclitaxel for locally recurrent or metastatic HER2-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Taxol (paclitaxel)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 4 | Status: WITHDRAWN